CYP2C8 and heart disorder: These include clinically important interactions between CYP2C8 substrates and heart disease medications gemfibrozil and clopidogrel, due to time-dependent inhibition or mechanism-based inactivation of CYP2C8 by the acyl β–d–glucuronide (acyl glucuronide) metabolites of these drugs [11,13,14].